Dr. Murphy has more than 15 years experience in drug development and evaluation, both from the academic and industry perspective. He most recently served as the Chief Medical Officer of Eiger Biosciences. Previously, Dr. Murphy was Chief Medical Officer at Valeant Pharmaceuticals International (VRX) where his responsibilities also included oversight of Global Medical Affairs and Pharmacovigilance. Dr. Murphy also served as Medical Director, then Vice President of Marketing and Commercial Strategy of Hepatology for InterMune, Inc. (ITMN). Prior to InterMune, Dr. Murphy was Medical Director of North America for Antivirals/Interferons at Hoffmann-LaRoche. Prior to joining industry, Dr. Murphy was Assistant Professor of Medicine at New York Medical College and was Director of the Clinical Strategies Programs at St. Vincent's Hospital in New York City, the lead hospital of the Catholic Healthcare Network of New York. Dr. Murphy is board-certified in internal medicine and completed his residency in internal medicine at Tufts-New England Medical Center and served as Chief Medical Resident in the Boston University program. He went on to complete parallel fellowship tracts at Harvard Medical School, one in internal medicine/clinical epidemiology at the Massachusetts General Hospital and the other in medical ethics addressing issues of distributive justice and access to care. Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business.

Ms. Cunning brings over 20 years of extensive expertise in U.S. sales, marketing, global new product development, commercialization, and lifecycle management in the biopharmaceutical industry. Prior to joining Nemus, Ms. Cunning served as Director, New Products, U.S. Eye Care at Allergan, where she led the creation of the business unit strategy for the U.S. ocular franchise. She was the Associate Director of Marketing at Amylin Pharmaceuticals, leading the global life-cycle management for Byetta®. Additionally, she held leadership positions at Valeant Pharmaceuticals, a multi-billion dollar pharmaceutical company, as the global marketing and commercial development lead for both the viral hepatitis and HIV franchises. Prior to joining Valeant, Ms. Cunning worked in Hepsera® marketing at Gilead Sciences and sales in HIV and respiratory medicine at GlaxoSmithKline. Ms. Cunning earned a bachelor's degree in biology from West Virginia University.